iBio established a new at-the-market equity offering program of up to $100 million through an Open Market Sale Agreement with Jefferies, subject to the effectiveness of a new Form S-3 shelf. Jefferies will act as sales agent, earning up to a 3% commission, with sales potentially occurring on the Nasdaq Capital Market or via other permitted methods. In connection with the new facility, iBio terminated its prior ATM program with Chardan Capital Markets and Craig-Hallum Capital Group, finishing further sales under the earlier prospectus. The actions are intfinished to enhance the company’s flexibility to raise capital.
New agreement details:
- Agreement type: Open Market Sale Agreement (ATM equity offering up to $100,000,000)
- Counterparty: Jefferies
- Signed / Effective: Feb 27 2026 / Feb 27 2026
- Duration / Termination: At will
- Reason: Increase capital-raising flexibility and liquidity
Terminated agreement details:
- Agreement terminated: At Market Issuance Sales Agreement (ATM equity program up to $7,350,000)
- Counterparty: Chardan Capital Markets and Craig-Hallum Capital Group
- Original agreement date: Jul 03 2024
- Termination date: Feb 23 2026
- Termination type: Early
- Exit fees / payments: None
- Reason: Replace prior ATM with new Jefferies program
Original SEC Filing: iBio, Inc. [ IBIO ] – 8-K – Feb. 27, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.
Leave a Reply